AACR
April 13, 2022
American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022
Year
2022
Target
RVU120 (CDK8/CDK19), RVU 305 (PRMT5)
Assets in this page
Download assets
- pdf file
"RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"
Download - pdf file
"Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers"
Download - pdf file
"RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors"
Download